Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Terbicol
- Development stage
- Phase 2
- Lead developer
- Dermal Laboratories
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
Terbicol is a terbinafine-based antifungal shampoo developed by Dermal Laboratories for the topical treatment of severe dandruff (pityriasis capitis) and seborrhoeic dermatitis. The active ingredient, terbinafine, is a small molecule allylamine that acts by inhibiting squalene epoxidase (squalene monooxygenase), a key enzyme in the fungal ergosterol biosynthetic pathway. This inhibition leads to a deficiency in ergosterol and an accumulation of squalene within the fungal cell, resulting in membrane disruption and cell death. Terbicol was investigated in a Phase 2 clinical trial in the United Kingdom to assess its efficacy and safety when used twice weekly in patients with Malassezia-related scalp conditions.
- Brand names
- Terbicol
02
Targets
SQLE (Squalene monooxygenase)
Beyond the preview
Go deeper on Terbicol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Terbicol.